These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38621200)

  • 1. Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia.
    van Weelderen RE; Harrison CJ; Klein K; Jiang Y; Abrahamsson J; Alonzo T; Aplenc R; Arad-Cohen N; Bart-Delabesse E; Buldini B; De Moerloose B; Dworzak MN; Elitzur S; Fernández Navarro JM; Gamis A; Gerbing RB; Goemans BF; de Groot-Kruseman HA; Guest E; Ha SY; Hasle H; Kelaidi C; Lapillonne H; Leverger G; Locatelli F; Miyamura T; Norén-Nyström U; Polychronopoulou S; Rasche M; Rubnitz JE; Stary J; Tierens A; Tomizawa D; Zwaan CM; Kaspers GJL
    Blood Adv; 2024 Jun; 8(12):3200-3213. PubMed ID: 38621200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study.
    Coenen EA; Raimondi SC; Harbott J; Zimmermann M; Alonzo TA; Auvrignon A; Beverloo HB; Chang M; Creutzig U; Dworzak MN; Forestier E; Gibson B; Hasle H; Harrison CJ; Heerema NA; Kaspers GJ; Leszl A; Litvinko N; Lo Nigro L; Morimoto A; Perot C; Reinhardt D; Rubnitz JE; Smith FO; Stary J; Stasevich I; Strehl S; Taga T; Tomizawa D; Webb D; Zemanova Z; Pieters R; Zwaan CM; van den Heuvel-Eibrink MM
    Blood; 2011 Jun; 117(26):7102-11. PubMed ID: 21551233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KMT2A (MLL) rearrangements observed in pediatric/young adult T-lymphoblastic leukemia/lymphoma: A 10-year review from a single cytogenetic laboratory.
    Peterson JF; Baughn LB; Pearce KE; Williamson CM; Benevides Demasi JC; Olson RM; Goble TA; Meyer RG; Greipp PT; Ketterling RP
    Genes Chromosomes Cancer; 2018 Nov; 57(11):541-546. PubMed ID: 30203571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukemia with t(10;11)(p11-12;q23.3): Results of Russian Pediatric AML registration study.
    Zerkalenkova E; Lebedeva S; Kazakova A; Tsaur G; Starichkova Y; Timofeeva N; Soldatkina O; Aprelova E; Popov A; Ponomareva N; Baidun L; Meyer C; Novichkova G; Maschan M; Maschan A; Marschalek R; Olshanskaya Y
    Int J Lab Hematol; 2019 Apr; 41(2):287-292. PubMed ID: 30624859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia.
    Vetro C; Haferlach T; Meggendorfer M; Stengel A; Jeromin S; Kern W; Haferlach C
    Cancer Genet; 2020 Jan; 240():15-22. PubMed ID: 31698332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia patients with KMT2A rearrangement; A nationwide retrospective analysis in Japan.
    Miyamura T; Kudo K; Tabuchi K; Ishida H; Tomizawa D; Adachi S; Goto H; Yoshida N; Inoue M; Koh K; Sasahara Y; Fujita N; Kakuda H; Noguchi M; Hiwatari M; Hashii Y; Kato K; Atsuta Y; Okamoto Y
    Leuk Res; 2019 Dec; 87():106263. PubMed ID: 31707119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GAS6 Oncogene and Reverse MLLT3-KMT2A Duplications in an Infant with Acute Myeloid Leukemia and a Novel Complex Hyperdiploid Karyotype: Detailed High-Resolution Molecular Cytogenetic Studies.
    Capela de Matos RR; Ney Garcia DR; Cifoni E; Othman MAK; Tavares de Souza M; Carboni EK; Ferreira GM; Liehr T; Ribeiro RC; M Silva ML
    Cytogenet Genome Res; 2017; 152(1):33-37. PubMed ID: 28595195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterization of KMT2A fusion partner genes in 13 cases of pediatric leukemia with complex or cryptic karyotypes.
    Ney Garcia DR; de Souza MT; de Figueiredo AF; Othman MAK; Rittscher K; Abdelhay E; Capela de Matos RR; Meyer C; Marschalek R; Land MGP; Liehr T; Ribeiro RC; Silva MLM
    Hematol Oncol; 2017 Dec; 35(4):760-768. PubMed ID: 27282883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric
    Pollard JA; Guest E; Alonzo TA; Gerbing RB; Loken MR; Brodersen LE; Kolb EA; Aplenc R; Meshinchi S; Raimondi SC; Hirsch B; Gamis AS
    J Clin Oncol; 2021 Oct; 39(28):3149-3160. PubMed ID: 34048275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/
    Bill M; Mrózek K; Kohlschmidt J; Eisfeld AK; Walker CJ; Nicolet D; Papaioannou D; Blachly JS; Orwick S; Carroll AJ; Kolitz JE; Powell BL; Stone RM; de la Chapelle A; Byrd JC; Bloomfield CD
    Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26340-26346. PubMed ID: 33020282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A New Complex Karyotype Involving a KMT2A-r Variant Three-Way Translocation in a Rare Clinical Presentation of a Pediatric Patient with Acute Myeloid Leukemia.
    Capela de Matos RR; Ney Garcia DR; Othman MAK; Moura Ferreira G; Melo JB; Carreira IM; Meyer C; Marschalek R; Costa ES; Land MGP; Liehr T; Ribeiro RC; Silva MLM
    Cytogenet Genome Res; 2019; 157(4):213-219. PubMed ID: 30974445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute leukemias harboring KMT2A/MLLT10 fusion: a 10-year experience from a single genomics laboratory.
    Peterson JF; Sukov WR; Pitel BA; Smoley SA; Pearce KE; Meyer RG; Williamson CM; Smadbeck JB; Vasmatzis G; Hoppman NL; Greipp PT; Baughn LB; Ketterling RP
    Genes Chromosomes Cancer; 2019 Aug; 58(8):567-577. PubMed ID: 30707474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational landscape and clinical outcome of pediatric acute myeloid leukemia with 11q23/KMT2A rearrangements.
    Yuen KY; Liu Y; Zhou YZ; Wang Y; Zhou DH; Fang JP; Xu LH
    Cancer Med; 2023 Jan; 12(2):1418-1430. PubMed ID: 35833755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Umbilical cord blood transplantation can overcome the poor prognosis of KMT2A-MLLT3 acute myeloid leukemia and can lead to good GVHD-free/relapse-free survival.
    Tong J; Zhang L; Liu H; Xu X; Zheng C; Yao W; Zhu X; Tang B; Wan X; Song K; Zhang X; Sun G; Sun Z
    Ann Hematol; 2021 May; 100(5):1303-1309. PubMed ID: 33469688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia.
    Kanayama T; Imamura T; Kawabe Y; Osone S; Tahara J; Iwasaki F; Miyagawa N; Goto H; Imashuku S; Hosoi H
    Int J Hematol; 2018 Dec; 108(6):665-669. PubMed ID: 30143999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Developments and Evolving Therapeutic Strategies in KMT2A-Rearranged Acute Leukemia.
    Yin L; Wan L; Zhang Y; Hua S; Shao X
    Cancer Med; 2024 Oct; 13(20):e70326. PubMed ID: 39428967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.
    von Neuhoff C; Reinhardt D; Sander A; Zimmermann M; Bradtke J; Betts DR; Zemanova Z; Stary J; Bourquin JP; Haas OA; Dworzak MN; Creutzig U
    J Clin Oncol; 2010 Jun; 28(16):2682-9. PubMed ID: 20439630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML.
    Matsuo H; Yoshida K; Nakatani K; Harata Y; Higashitani M; Ito Y; Kamikubo Y; Shiozawa Y; Shiraishi Y; Chiba K; Tanaka H; Okada A; Nannya Y; Takeda J; Ueno H; Kiyokawa N; Tomizawa D; Taga T; Tawa A; Miyano S; Meggendorfer M; Haferlach C; Ogawa S; Adachi S
    Blood Adv; 2020 Oct; 4(19):4623-4631. PubMed ID: 32991719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
    Gröschel S; Schlenk RF; Engelmann J; Rockova V; Teleanu V; Kühn MW; Eiwen K; Erpelinck C; Havermans M; Lübbert M; Germing U; Schmidt-Wolf IG; Beverloo HB; Schuurhuis GJ; Ossenkoppele GJ; Schlegelberger B; Verdonck LF; Vellenga E; Verhoef G; Vandenberghe P; Pabst T; Bargetzi M; Krauter J; Ganser A; Valk PJ; Löwenberg B; Döhner K; Döhner H; Delwel R
    J Clin Oncol; 2013 Jan; 31(1):95-103. PubMed ID: 23008312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent
    Matsuo H; Yoshida K; Fukumura K; Nakatani K; Noguchi Y; Takasaki S; Noura M; Shiozawa Y; Shiraishi Y; Chiba K; Tanaka H; Okada A; Nannya Y; Takeda J; Ueno H; Shiba N; Yamato G; Handa H; Ono Y; Hiramoto N; Ishikawa T; Usuki K; Ishiyama K; Miyawaki S; Itonaga H; Miyazaki Y; Kawamura M; Yamaguchi H; Kiyokawa N; Tomizawa D; Taga T; Tawa A; Hayashi Y; Mano H; Miyano S; Kamikubo Y; Ogawa S; Adachi S
    Blood Adv; 2018 Nov; 2(21):2879-2889. PubMed ID: 30381403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.